The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Neoplasm, Residual

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Neoplasm, Residual


Psychiatry related information on Neoplasm, Residual


High impact information on Neoplasm, Residual

  • These results suggest that rIL-2-activated NK cells may be used to purge peripheral blood HP cell preparations of residual tumor cells before hematopoietic reconstitution [7].
  • Elevated levels of the 100K MAA were associated with evidence of residual tumor (P less than .008): Only 3 of 13 patients with no evidence of tumor had abnormal values, whereas 9 of 16 patients with evident tumor had increased serum levels [8].
  • In addition, weekly injections of 25 micrograms MCA-F TSTA decreased the tumor recurrence rate and increased the survival times of hosts with recurrent neoplastic disease by virtue of residual tumor cells following resection of 2-cm masses [9].
  • The amount of glucan injected and the quantity of residual tumor appeared to be related [10].
  • To date, studies of VEGF antagonists have primarily focused on halting progression in models of minimal residual cancer [11].

Chemical compound and disease context of Neoplasm, Residual


Biological context of Neoplasm, Residual


Anatomical context of Neoplasm, Residual


Gene context of Neoplasm, Residual

  • These results indicate that qrtPCR monitoring of PML-RAR alpha NQ can identify patients at high risk of relapse and suggest that clinically practical PB NQ monitoring at more frequent FUP intervals may improve predictive accuracy for relapse or continuing CR in patients with persistent, fluctuating minimal residual disease levels [27].
  • Interleukin-2 (IL-2) therapy may improve immune reconstitution and reduce the risk of leukemic relapse in the setting of minimal residual disease by augmenting cytotoxic effector mechanisms directed at residual malignant cells [28].
  • These results indicate that FLT3 mutations are secondary events in leukemogenesis, are unstable, and thus should be used cautiously for the detection of minimal residual disease [29].
  • Thus, the NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease in AML and a potential candidate for alternative and targeted treatments [30].
  • Finally, our data show that HOX11L2 expression was a suitable marker for minimal residual disease follow-up and was significantly associated with relapse (P =.02) [31].

Analytical, diagnostic and therapeutic context of Neoplasm, Residual


  1. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. Chan, A.T., Lo, Y.M., Zee, B., Chan, L.Y., Ma, B.B., Leung, S.F., Mo, F., Lai, M., Ho, S., Huang, D.P., Johnson, P.J. J. Natl. Cancer Inst. (2002) [Pubmed]
  2. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Meyer, C., Schneider, B., Reichel, M., Angermueller, S., Strehl, S., Schnittger, S., Schoch, C., Jansen, M.W., van Dongen, J.J., Pieters, R., Haas, O.A., Dingermann, T., Klingebiel, T., Marschalek, R. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  3. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Yokota, S., Hansen-Hagge, T.E., Ludwig, W.D., Reiter, A., Raghavachar, A., Kleihauer, E., Bartram, C.R. Blood (1991) [Pubmed]
  4. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Lee, M.S., Kantarjian, H., Talpaz, M., Freireich, E.J., Deisseroth, A., Trujillo, J.M., Stass, S.A. Blood (1992) [Pubmed]
  5. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Hakimian, D., Tallman, M.S., Kiley, C., Peterson, L. Blood (1993) [Pubmed]
  6. Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease. Goldman, J.M., Kaeda, J.S., Cross, N.C., Hochhaus, A., Hehlmann, R. Blood (1999) [Pubmed]
  7. The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors. Nagler, A., Greenberg, P.L., Lanier, L.L., Phillips, J.H. J. Exp. Med. (1988) [Pubmed]
  8. Measurement of a monoclonal antibody-defined, melanoma-associated antigen in human sera: correlation of circulating antigen levels with tumor burden. Morgan, A.C., Crane, M.M., Rossen, R.D. J. Natl. Cancer Inst. (1984) [Pubmed]
  9. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens. Kahan, B.D., Tanaka, T., Pellis, N.R. J. Natl. Cancer Inst. (1980) [Pubmed]
  10. Macrophage-mediated destruction of human malignant cells in vivo. Mansell, P.W., Ichinose, H., Reed, R.J., Krementz, E.T., McNamee, R., Di Luzio, N.R. J. Natl. Cancer Inst. (1975) [Pubmed]
  11. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Huang, J., Frischer, J.S., Serur, A., Kadenhe, A., Yokoi, A., McCrudden, K.W., New, T., O'Toole, K., Zabski, S., Rudge, J.S., Holash, J., Yancopoulos, G.D., Yamashiro, D.J., Kandel, J.J. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  12. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Miller, W.H., Kakizuka, A., Frankel, S.R., Warrell, R.P., DeBlasio, A., Levine, K., Evans, R.M., Dmitrovsky, E. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  13. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Robertson, L.E., Huh, Y.O., Butler, J.J., Pugh, W.C., Hirsch-Ginsberg, C., Stass, S., Kantarjian, H., Keating, M.J. Blood (1992) [Pubmed]
  14. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Zwicky, C.S., Maddocks, A.B., Andersen, N., Gribben, J.G. Blood (1996) [Pubmed]
  15. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Marina, N.M., Cushing, B., Giller, R., Cohen, L., Lauer, S.J., Ablin, A., Weetman, R., Cullen, J., Rogers, P., Vinocur, C., Stolar, C., Rescorla, F., Hawkins, E., Heifetz, S., Rao, P.V., Krailo, M., Castleberry, R.P. J. Clin. Oncol. (1999) [Pubmed]
  16. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Fisher, B., Gunduz, N., Saffer, E.A. Cancer Res. (1983) [Pubmed]
  17. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Crescenzi, M., Seto, M., Herzig, G.P., Weiss, P.D., Griffith, R.C., Korsmeyer, S.J. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  18. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Stassi, G., Todaro, M., Zerilli, M., Ricci-Vitiani, L., Di Liberto, D., Patti, M., Florena, A., Di Gaudio, F., Di Gesù, G., De Maria, R. Cancer Res. (2003) [Pubmed]
  19. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Lambooy, L.H., Gidding, C.E., van den Heuvel, L.P., Hulsbergen-van de Kaa, C.A., Ligtenberg, M., Bökkerink, J.P., De Abreu, R.A. Clin. Cancer Res. (2003) [Pubmed]
  20. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Akahira, J., Sugihashi, Y., Suzuki, T., Ito, K., Niikura, H., Moriya, T., Nitta, M., Okamura, H., Inoue, S., Sasano, H., Okamura, K., Yaegashi, N. Clin. Cancer Res. (2004) [Pubmed]
  21. Detection and quantification of residual disease in chronic myelogenous leukemia. Hochhaus, A., Weisser, A., La Rosée, P., Emig, M., Müller, M.C., Saussele, S., Reiter, A., Kuhn, C., Berger, U., Hehlmann, R., Cross, N.C. Leukemia (2000) [Pubmed]
  22. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Slavin, S. Blood (2006) [Pubmed]
  23. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J.M., Melo, J.V. Blood (1998) [Pubmed]
  24. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Smith, I.C., Heys, S.D., Hutcheon, A.W., Miller, I.D., Payne, S., Gilbert, F.J., Ah-See, A.K., Eremin, O., Walker, L.G., Sarkar, T.K., Eggleton, S.P., Ogston, K.N. J. Clin. Oncol. (2002) [Pubmed]
  25. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. van Rhenen, A., Feller, N., Kelder, A., Westra, A.H., Rombouts, E., Zweegman, S., van der Pol, M.A., Waisfisz, Q., Ossenkoppele, G.J., Schuurhuis, G.J. Clin. Cancer Res. (2005) [Pubmed]
  26. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. Yeung, H.W., Humm, J.L., Larson, S.M. J. Nucl. Med. (2000) [Pubmed]
  27. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Gallagher, R.E., Yeap, B.Y., Bi, W., Livak, K.J., Beaubier, N., Rao, S., Bloomfield, C.D., Appelbaum, F.R., Tallman, M.S., Slack, J.L., Willman, C.L. Blood (2003) [Pubmed]
  28. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Heslop, H.E., Gottlieb, D.J., Bianchi, A.C., Meager, A., Prentice, H.G., Mehta, A.B., Hoffbrand, A.V., Brenner, M.K. Blood (1989) [Pubmed]
  29. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T., Linch, D.C. Blood (2002) [Pubmed]
  30. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Cazzaniga, G., Dell'Oro, M.G., Mecucci, C., Giarin, E., Masetti, R., Rossi, V., Locatelli, F., Martelli, M.F., Basso, G., Pession, A., Biondi, A., Falini, B. Blood (2005) [Pubmed]
  31. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Ballerini, P., Blaise, A., Busson-Le Coniat, M., Su, X.Y., Zucman-Rossi, J., Adam, M., van den Akker, J., Perot, C., Pellegrino, B., Landman-Parker, J., Douay, L., Berger, R., Bernard, O.A. Blood (2002) [Pubmed]
  32. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Kozu, T., Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y., Asou, H., Kamada, N., Ohki, M. Blood (1993) [Pubmed]
  33. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Miyamura, K., Tanimoto, M., Morishima, Y., Horibe, K., Yamamoto, K., Akatsuka, M., Kodera, Y., Kojima, S., Matsuyama, K., Hirabayashi, N. Blood (1992) [Pubmed]
  34. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Ackerstein, A., Kedar, E., Slavin, S. Blood (1991) [Pubmed]
  35. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Hunger, S.P., Fall, M.Z., Camitta, B.M., Carroll, A.J., Link, M.P., Lauer, S.J., Mahoney, D.H., Pullen, D.J., Shuster, J.J., Steuber, C.P., Cleary, M.L. Blood (1998) [Pubmed]
  36. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. Laczika, K., Novak, M., Hilgarth, B., Mitterbauer, M., Mitterbauer, G., Scheidel-Petrovic, A., Scholten, C., Thalhammer-Scherrer, R., Brugger, S., Keil, F., Schwarzinger, I., Haas, O.A., Lechner, K., Jaeger, U. J. Clin. Oncol. (1998) [Pubmed]
WikiGenes - Universities